Literature DB >> 22718128

Dynamic longitudinal antibody responses during Borrelia burgdorferi infection and antibiotic treatment of rhesus macaques.

Monica E Embers1, Nicole R Hasenkampf, Mary B Jacobs, Mario T Philipp.   

Abstract

Infection with Borrelia burgdorferi elicits robust yet disparate antibody responses in infected individuals. A longitudinal assessment of antibody responses to multiple diagnostic antigens following experimental infection and treatment has not previously been reported. Our goal was to identify a combination of antigens that could indicate infection at all phases of disease and response to antibiotic treatment. Because the rhesus macaque recapitulates the hallmark signs and disease course of human Lyme disease, we examined the specific antibody responses to multiple antigens of B. burgdorferi following infection of macaques. Five macaques infected with strain B31 and 12 macaques infected with strain JD1 were included in the analysis. Approximately half of these animals were treated with antibiotics at 4 to 6 months postinoculation. Antibody responses to several B. burgdorferi recombinant antigens, including OspC, DbpA, BBK32, OspA, and OppA-2, were measured at multiple points throughout infection. We have previously shown a decline in the response to the C6 peptide following antibiotic treatment. Responses to OspA and OspC, however, were variable over time among individuals, irrespective of antibiotic treatment. Not every individual responded to BBK32, but anti-DbpA IgG levels were uniformly high and remained elevated for all animals. All responded to OppA-2, with a decline posttreatment that was slow and incomplete. This is the first demonstration of B. burgdorferi OppA-2 antigenicity in nonhuman primates. The combination of DbpA, OspC, OspA, and OppA-2 with the C6 diagnostic peptide has the potential to detect infection throughout all disease phases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22718128      PMCID: PMC3416093          DOI: 10.1128/CVI.00228-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  46 in total

1.  Humoral immune response associated with lyme borreliosis in nonhuman primates: analysis by immunoblotting and enzyme-linked immunosorbent assay with sonicates or recombinant proteins.

Authors:  A R Pachner; D Dail; L Li; L Gurey; S Feng; E Hodzic; S Barthold
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

2.  Temporal analysis of the antigenic composition of Borrelia burgdorferi during infection in rabbit skin.

Authors:  Timothy R Crother; Cheryl I Champion; Julian P Whitelegge; Rodrigo Aguilera; Xiao-Yang Wu; David R Blanco; James N Miller; Michael A Lovett
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

3.  Outer-surface protein C of the Lyme disease spirochete: a protein induced in ticks for infection of mammals.

Authors:  Dorothee Grimm; Kit Tilly; Rebecca Byram; Philip E Stewart; Jonathan G Krum; Dawn M Bueschel; Tom G Schwan; Paul F Policastro; Abdallah F Elias; Patricia A Rosa
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-17       Impact factor: 11.205

4.  Comparison of Western immunoblotting and the C6 Lyme antibody test for laboratory detection of Lyme disease.

Authors:  Elena Mogilyansky; Chien Chang Loa; Martin E Adelson; Eli Mordechai; Richard C Tilton
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

5.  Simultaneous transmission of Borrelia burgdorferi and Babesia microti by individual nymphal Ixodes dammini ticks.

Authors:  J Piesman; T C Hicks; R J Sinsky; G Obiri
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 5.948

6.  Recombinant OspC from Borrelia burgdorferi sensu stricto, B. afzelii and B. garinii in the serodiagnosis of Lyme borreliosis.

Authors:  Jaana Panelius; Pekka Lahdenne; Tero Heikkilä; Miikka Peltomaa; Jarmo Oksi; Ilkka Seppälä
Journal:  J Med Microbiol       Date:  2002-09       Impact factor: 2.472

7.  C6 test as an indicator of therapy outcome for patients with localized or disseminated lyme borreliosis.

Authors:  Mario T Philipp; Adriana R Marques; Paul T Fawcett; Leonard G Dally; Dale S Martin
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

8.  Effects of environmental changes on expression of the oligopeptide permease (opp) genes of Borrelia burgdorferi.

Authors:  Xing-Guo Wang; Bo Lin; J Michael Kidder; Samuel Telford; Linden T Hu
Journal:  J Bacteriol       Date:  2002-11       Impact factor: 3.490

9.  Diagnosis of Lyme neuroborreliosis with antibodies to recombinant proteins DbpA, BBK32, and OspC, and VlsE IR6 peptide.

Authors:  Jaana Panelius; Pekka Lahdenne; Harri Saxén; Sten-Anders Carlsson; Tero Heikkilä; Miikka Peltomaa; Anneli Lauhio; Ilkka Seppälä
Journal:  J Neurol       Date:  2003-11       Impact factor: 4.849

10.  Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates.

Authors:  Rendi Murphree Bacon; Brad J Biggerstaff; Martin E Schriefer; Robert D Gilmore; Mario T Philipp; Allen C Steere; Gary P Wormser; Adriana R Marques; Barbara J B Johnson
Journal:  J Infect Dis       Date:  2003-04-02       Impact factor: 5.226

View more
  10 in total

1.  Identification of lysine residues in the Borrelia burgdorferi DbpA adhesin required for murine infection.

Authors:  Danielle E Fortune; Yi-Pin Lin; Ranjit K Deka; Ashley M Groshong; Brendan P Moore; Kayla E Hagman; John M Leong; Diana R Tomchick; Jon S Blevins
Journal:  Infect Immun       Date:  2014-05-19       Impact factor: 3.441

2.  Bacterial heterogeneity is a requirement for host superinfection by the Lyme disease spirochete.

Authors:  Artem S Rogovskyy; Troy Bankhead
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

Review 3.  Improving rigor and reproducibility in nonhuman primate research.

Authors:  Eliza Bliss-Moreau; Rama R Amara; Elizabeth A Buffalo; Ricki J Colman; Monica E Embers; John H Morrison; Ellen E Quillen; Jonah B Sacha; Charles T Roberts
Journal:  Am J Primatol       Date:  2021-09-20       Impact factor: 3.014

4.  Development of a Multiantigen Panel for Improved Detection of Borrelia burgdorferi Infection in Early Lyme Disease.

Authors:  Lauren J Lahey; Michael W Panas; Rong Mao; Michelle Delanoy; John J Flanagan; Steven R Binder; Alison W Rebman; Jose G Montoya; Mark J Soloski; Allen C Steere; Raymond J Dattwyler; Paul M Arnaboldi; John N Aucott; William H Robinson
Journal:  J Clin Microbiol       Date:  2015-10-07       Impact factor: 5.948

5.  Identification of OppA2 linear epitopes as serodiagnostic markers for Lyme disease.

Authors:  Giacomo Signorino; Paul M Arnaboldi; Mary M Petzke; Raymond J Dattwyler
Journal:  Clin Vaccine Immunol       Date:  2014-03-12

6.  Five-Antigen Fluorescent Bead-Based Assay for Diagnosis of Lyme Disease.

Authors:  Monica E Embers; Nicole R Hasenkampf; Mary B Barnes; Elizabeth S Didier; Mario T Philipp; Amanda C Tardo
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

Review 7.  Quantitative multiplexed strategies for human Lyme disease serological testing.

Authors:  Eunice Chou; Armond Minor; Nathaniel C Cady
Journal:  Exp Biol Med (Maywood)       Date:  2021-04-01

8.  Variable manifestations, diverse seroreactivity and post-treatment persistence in non-human primates exposed to Borrelia burgdorferi by tick feeding.

Authors:  Monica E Embers; Nicole R Hasenkampf; Mary B Jacobs; Amanda C Tardo; Lara A Doyle-Meyers; Mario T Philipp; Emir Hodzic
Journal:  PLoS One       Date:  2017-12-13       Impact factor: 3.240

9.  Serological Analysis Identifies Consequential B Cell Epitopes on the Flexible Linker and C-Terminus of Decorin Binding Protein A (DbpA) from Borrelia burgdorferi.

Authors:  Elaheh Movahed; David J Vance; Dylan Ehrbar; Greta Van Slyke; Jennifer Yates; Karen Kullas; Michael Rudolph; Nicholas J Mantis
Journal:  mSphere       Date:  2022-07-25       Impact factor: 5.029

10.  Vaccination against Lyme disease: Are we ready for it?

Authors:  Patricia Kaaijk; Willem Luytjes
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.